Aug 03, 2022
Issued Claims for Single-Chain Chimeric Polypeptide and Composition Claims for Lead Product Candidate, HCW9302 MIRAMAR, Fla., Aug. 03, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel
May 05, 2022
Cytokine-Based Fusion Proteins to Activate and Expand Memory-Like NK Cells  Without Using Feeder Cells Sufficient for Off-the-Shelf Multi-Dose Adoptive Cell Therapy Cytokine-Based Fusion Proteins to Expand Human Regulatory T Cells That Circumvents Need for Magnetic Beads For Adoptive Cell Therapy
Jan 24, 2022
UM cleared to proceed with clinical trial to evaluate HCW9218 in various advanced solid tumors, such as breast, ovarian, prostate, and colorectal cancers MIRAMAR, Fla., Jan. 24, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a biopharmaceutical company focused on
Displaying 1 - 10 of 13